Everest Medicines is a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Asian markets.
The management team of Everest Medicines has deep expertise and an extensive track record of high-quality clinical development, regulatory affairs, CMC, business development and operations both in China and with leading global pharmaceutical companies. Everest Medicines has built a portfolio of eleven potentially global first-in-class or best-in-class molecules, many of which are in late-stage clinical development. The Company’s therapeutic areas of interest include oncology, autoimmune disorders, cardio-renal diseases and infectious diseases.
By 2030, we will be a top 3 integrated biopharma in Asia Pacific, who creates social impact by delivering our specialty portfolio and sustainable growth.
Better Medicines, Better Life
Ownership: Our people are owners who take actions, make decisions and accountable for outcomes
Respect and Care: Our people are our most valuable assets
Collaboration: Our partnerships allow us to accelerate the development of high quality innovative medicines
Science Driven: We leverage our skills and expertise with a passion to follow the science
Patient First: We start with understanding the needs of patients
